Xin Lang Cai Jing·2025-12-16 07:41Core Viewpoint - The company, Junshi Biosciences, is focused on becoming a leading innovative pharmaceutical company with a complete industry chain capability, from drug discovery to commercialization, and is actively developing vaccines and monoclonal antibodies for various diseases, including monkeypox [2][3]. Company Overview - Junshi Biosciences was established on December 27, 2012, and went public on July 15, 2020. The company is headquartered in Shanghai and specializes in the research and commercialization of monoclonal antibodies and other therapeutic protein drugs [7]. - The main revenue sources for the company include drug sales (90.67%), technology licensing and royalties (8.74%), and technical services (0.59%) [7]. Financial Performance - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, representing a year-on-year growth of 42.06%. However, the net profit attributable to the parent company was -596 million yuan, which is a 35.72% increase compared to the previous year [8]. Product Development - The company has developed a comprehensive pipeline of innovative drugs, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2]. - Junshi Biosciences is also developing Tifcemalimab, the world's first anti-BTLA monoclonal antibody, which is currently in Phase III clinical trials [2]. Collaborations and Research - On October 27, 2023, Junshi Biosciences announced collaborations with several research institutions and universities to develop a recombinant protein vaccine for monkeypox, with related products currently in preclinical development [3].